Reset
Id
Protein
PTM type
Site
Species
Disease
Celline
Drug
Regulatory
Confidence score(level)
Ref.
acc01201 Growth hormone-inducible transmembrane protein oxidation Met336 human Colon Cancer LS174 Algae extract Positive 5.0 (High) PXD041686
acc01202 Mitochondrial import receptor subunit TOM22 homolog oxidation Met108 human Colon Cancer LS174 Algae extract Positive 5.0 (High) PXD041686
acc01203 Vesicle-associated membrane protein-associated protein A oxidation Met132 human Colon Cancer LS174 Algae extract Positive 5.0 (High) PXD041686
acc01204 Ribosome-binding protein 1 oxidation Met1028 human Colon Cancer LS174 Algae extract Positive 5.0 (High) PXD041686
acc01205 Glutathione S-transferase kappa 1 oxidation Met147 human Colon Cancer LS174 Algae extract Positive 5.0 (High) PXD041686
acc01206 Large ribosomal subunit protein eL36 oxidation Met97 human Colon Cancer LS174 Algae extract Positive 5.0 (High) PXD041686
acc01207 Chromatin target of PRMT1 protein oxidation Met224 human Colon Cancer LS174 Algae extract Positive 5.0 (High) PXD041686
acc01208 Histone H3.1 acetylation Lys24 human Endometrial Cancer RL95-2 DEAB Negative 5.0 (High) PXD052364
acc01209 Histone H3.3C acetylation Lys24 human Endometrial Cancer RL95-2 DEAB Negative 5.0 (High) PXD052364
acc01210 Histone H3.3 acetylation Lys24 human Endometrial Cancer RL95-2 DEAB Negative 5.0 (High) PXD052364
acc01211 Histone H3-7 acetylation Lys24 human Endometrial Cancer RL95-2 DEAB Negative 5.0 (High) PXD052364
acc01212 Histone H3.2 acetylation Lys24 human Endometrial Cancer RL95-2 DEAB Negative 5.0 (High) PXD052364
acc01213 Histone H3.1 acetylation Lys15 human Endometrial Cancer RL95-2 DEAB Negative 5.0 (High) PXD052364
acc01214 Histone H3.1t acetylation Lys15 human Endometrial Cancer RL95-2 DEAB Negative 5.0 (High) PXD052364
acc01215 Histone H3.3C acetylation Lys15 human Endometrial Cancer RL95-2 DEAB Negative 5.0 (High) PXD052364
acc01216 Histone H3.3 acetylation Lys15 human Endometrial Cancer RL95-2 DEAB Negative 5.0 (High) PXD052364
acc01217 Histone H3-7 acetylation Lys15 human Endometrial Cancer RL95-2 DEAB Negative 5.0 (High) PXD052364
acc01218 Histone H3.2 acetylation Lys15 human Endometrial Cancer RL95-2 DEAB Negative 5.0 (High) PXD052364
acc01219 Inosine-5'-monophosphate dehydrogenase 2 oxidation Met385 human Epidermoid Carcinoma A431 Gefitinib Negative 4.0 (Moderate) PXD000065
acc01220 Inosine-5'-monophosphate dehydrogenase 2 oxidation Met386 human Epidermoid Carcinoma A431 Gefitinib Negative 4.0 (Moderate) PXD000065
acc01221 Protein PAT1 homolog 1 oxidation Met144 human Epidermoid Carcinoma A431 Gefitinib Negative 4.0 (Moderate) PXD000065
acc01222 Protein transport protein Sec16A oxidation Met1432 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01223 U3 small nucleolar RNA-interacting protein 2 oxidation Met45 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01224 Histone H2B type 1-L oxidation Met60 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01225 Histone H2B type 1-M oxidation Met60 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01226 Histone H2B type 1-N oxidation Met60 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01227 Histone H2B type 1-H oxidation Met60 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01228 Histone H2B type 2-F oxidation Met60 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01229 Histone H2B type 1-C/E/F/G/I oxidation Met60 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01230 Histone H2B type 1-D oxidation Met60 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01231 Histone H2B type F-S oxidation Met60 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01232 Histone H2B type 1-K oxidation Met60 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01233 Histone H2B type 2-E oxidation Met60 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01234 Histone H2B type 1-B oxidation Met60 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01235 Histone H2B type 1-O oxidation Met60 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01236 Histone H2B type 1-J oxidation Met60 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01237 Histone H2B type 3-B oxidation Met60 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01238 Histone H2B type 1-L oxidation Met63 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01239 Histone H2B type 1-M oxidation Met63 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01240 Histone H2B type 1-N oxidation Met63 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01241 Histone H2B type 1-H oxidation Met63 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01242 Histone H2B type 2-F oxidation Met63 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01243 Histone H2B type 1-C/E/F/G/I oxidation Met63 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01244 Histone H2B type 1-D oxidation Met63 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01245 Histone H2B type F-S oxidation Met63 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01246 Histone H2B type 1-K oxidation Met63 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01247 Histone H2B type 2-E oxidation Met63 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01248 Histone H2B type 1-B oxidation Met63 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01249 Histone H2B type 1-O oxidation Met63 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861
acc01250 Histone H2B type 1-J oxidation Met63 human Lung Cancer PC9IR Gefitinib Negative 4.0 (Moderate) PXD000861